ALLO-182 / Allogene Therap - LARVOL DELTA

Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) - "Allogene Therapeutics...presented preclinical data on a novel off-the-shelf AlloCAR T product candidate targeting Claudin18.2 (CLDN18.2)-positive gastric and pancreatic tumors, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting....Data presented at SITC describes preclinical development of Allogene’s novel allogeneic CLDN18.2 CAR T product candidate with the potential to provide clinical benefit to patients with a single, off-the-shelf infusion....Research provides early validation of ALLO-182, an AlloCAR T candidate in the IND-enabling phase of development targeting Claudin18.2 for the treatment of patients with gastric and pancreatic cancers."

Preclinical • Gastric Cancer • Pancreatic Cancer

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) - "Allogene Therapeutics, Inc...today announced three preclinical poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 1-5, 2023, in San Diego, CA. These presentations will focus on the Company’s next generation AlloCAR T platform technologies and the foundation for an early-stage solid tumor product candidate, ALLO-182."

Preclinical • Oncology • Solid Tumor